article thumbnail

Debunked: USPTO Findings Should End False Pharma Patent Narratives

IP Watchdog

Patent and Trademark Office (USPTO), whose “Drug Patent and Exclusivity Study” effectively debunks the false narratives and bogus statistics that have been levied against pharmaceutical patents with significant effect in recent years.

article thumbnail

CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’

IP Watchdog

in its ongoing patent battle with Alnylam Pharmaceuticals over mRNA-based COVID-19 vaccine technology. Court of Appeals for the Federal Circuit (CAFC) affirmed a district court's finding of noninfringement in favor of Moderna, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

IP News: Barks & Bites for Friday, March 21 | IPWatchdog

IP Watchdog

This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. by BOE Technology. This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. by BOE Technology.

article thumbnail

Life Sciences Masters Panelists Say USPTO’s Controversial Anti-Pharma Rules are Unlikely to Progress

IP Watchdog

During IPWatchdog’s Life Sciences Masters program, which is taking place this week from Monday to Wednesday, panelists on the one hand breathed a sigh of relief that certain rule proposals considered most destructive to the industry seem unlikely to move forward, but on the other, lamented the overall negative tenor of the public debate around pharmaceutical (..)

article thumbnail

The Impact of Price Controls and Biologics on the Future of U.S. Pharmaceutical Innovation and Investment

IP Watchdog

Over the last several years the pharmaceutical industry has come under increased pressure.

article thumbnail

International IP Index Warns EU Efforts to Weaken Pharma IP Could Cause Investment to Migrate

IP Watchdog

While this years IP Index marked little movement among the top nations for IP legal frameworks, leaving the United States as the top nation overall for yet another year, stronger IP protections in Middle Eastern countries and efforts to weaken IP protections for pharmaceuticals in the EU and U.S.

article thumbnail

SCOTUS Asks SG for Input on Petition Seeking to Clarify Inducement Under Hatch-Waxman

IP Watchdog

Court of Appeals for the Federal Circuit (CAFC) was correct in reversing a district court’s grant of Hikma Pharmaceuticals’ motion to dismiss Amarin Pharma, Inc.’s Supreme Court today invited the Solicitor General of the United States to weigh in on whether the U.S. s complaint against it for induced infringement last June.